Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin and Ascorbic Acid for CIN Prevention
NCT03391830Completed
- Sponsor
- Mansoura University
- Start
- Jan 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of atorvastatin and ascorbic acid in contrast-induced nephropathy (CIN) (2 arms), sponsored by Mansoura University. Primary endpoint: Contrast-Induced Acute Kidney Injury at 3 days. Started Jan 2018; status: completed.
02
Drugs
atorvastatinascorbic acid
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on NCT03391830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03391830.